Complete trial list · post-viral overlap

All post-viral overlap clinical trials

155 interventional trials on ClinicalTrials.gov, all statuses · updated October 2026

Last updated 07 October 2026 from ClinicalTrials.gov. Trial statuses are refreshed automatically; check the registry record for the latest status and contact details.

35 recruiting16 not yet recruiting5 enrolling by invitation12 active, not recruiting62 completed5 terminated4 withdrawn16 unknown status

Every interventional study for overlapping or unspecified post-viral conditions (post-COVID fatigue, dysautonomia, POTS, post-viral syndromes not labelled as Long COVID or ME/CFS) in our ClinicalTrials.gov extract, regardless of status. Use this page to answer "has X been trialled in post-viral overlap?": search the page (Ctrl/Cmd-F) for a drug or intervention name, or browse the by-agent index.

Trials are grouped by status. Completed, terminated and withdrawn studies are included because they are often the most informative: a terminated trial may indicate futility, safety concerns or simply funding problems, so always read the record. Only trials currently open to enrolment are shown on the recruiting page.

Status badges: green = recruiting, blue = not yet recruiting, purple = enrolling by invitation, orange = active but closed to enrolment, grey = completed, red = terminated / withdrawn / suspended. "Unknown status" means the sponsor has not updated the record for more than two years past its expected completion date.
⚠️
Not medical advice. This page is an automatically compiled index of entries on ClinicalTrials.gov. Listing here is not an endorsement of any trial, sponsor or treatment, and trial status can change between our refreshes. Always confirm details on ClinicalTrials.gov and discuss participation with your own clinician.

Recruiting (35)

RecruitingPhase 1 NCT07398508
Sponsor: Stephen G. Kaler (Academic / non-profit / other)
Intervention(s): Droxidopa Oral Product
Start: Aug 2026  |  Primary completion: Jun 2030  |  Enrollment: 6 (estimated)
Record last updated: Oct 2026

This clinical trial will evaluate the safety, tolerability, dosing, and efficacy of Northera (Droxidopa) in children with Menkes disease aged 7 to 17 years who survived the major neurodegenerative and neurocognitive effects of Menkes disease through early Copper Histidinate treatment.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05493605
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild (Research network)
Intervention(s): Delivery Of A Long-Term Holter 21 Days Or Placement Of An Implantable Holter From The Outset So Syncope
Start: Mar 2023  |  Primary completion: Mar 2029  |  Enrollment: 150 (estimated)
Record last updated: Oct 2026

Heart damage by copper accumulation has been reported in Wilson's Disease. However, the disease epidemiology is still poorly understood. A number of studies on pediatric populations have not shown any significant cardiac involvement apart from early dysautonomia.

View on ClinicalTrials.gov ↗
RecruitingPhase 4 NCT07468604
Sponsor: University Health Network, Toronto (Academic / non-profit / other)
Intervention(s): 5 Ml Of 0.25% Bupivacaine With Epinephrine
Start: May 2026  |  Primary completion: May 2027  |  Enrollment: 78 (estimated)
Record last updated: Sep 2026

Post-COVID Condition (PCC) affects roughly 2.1 million Canadians, carrying an annual economic burden of CAD $7.8-50.6 billion. It presents across multiple organ systems with symptoms including fatigue, brain fog, palpitations, and orthostatic intolerance, at an annual cost of CAD $1,675-$7,340 per case.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT07655375
Sponsor: Guy Boeckxstaens (Academic / non-profit / other)
Intervention(s): Sample Collection
Start: Aug 2026  |  Primary completion: Oct 2027  |  Enrollment: 60 (estimated)
Record last updated: Sep 2026

Study evaluating the effect of UCB8600 on mast cell activation in the human gut: IBS is a disease characterized by abdominal pain and a change in stool. Treatment is limited to an adapted life style, dietary changes and medication to lessen cramps (spasmolytica), all of which have seen limited to no clinical success. Recently, we were able to demonstrate that mast cells play an active role in IBS symptoms.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05554107
Sponsor: Lund University (Academic / non-profit / other)
Intervention(s): Training Program
Start: Nov 2022  |  Primary completion: Mar 2028  |  Enrollment: 200 (estimated)
Record last updated: Sep 2026

Postural orthostatic tachycardia syndrome (POTS) is a disorder of unknown origin characterized by orthostatic intolerance and increased heart rate (HR) of ≥ 30 beats/minute during orthostasis in the absence of orthostatic hypotension.

View on ClinicalTrials.gov ↗
RecruitingPhase 4 NCT04308278
Sponsor: Labo'Life (Industry)
Intervention(s): 2Lebv® / 2Lxfs®
Start: Jan 2021  |  Primary completion: Aug 2028  |  Enrollment: 88 (estimated)
Record last updated: Aug 2026

Worldwide, 95% of adults are infected with Epstein-Barr Virus (EBV). These infections may cause different diseases. In most cases, EBV infection is asymptomatic because of a highly effective host immune response.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05400174
Sponsor: University of California, San Diego (Academic / non-profit / other)
Intervention(s): Tilt Table
Start: Dec 2021  |  Primary completion: Dec 2026  |  Enrollment: 60 (estimated)
Record last updated: Aug 2026

Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide. Besides causing symptoms that impair movement, PD also causes non-motor symptoms, such as problems thinking and orthostatic hypotension (OH), i.e., low blood pressure (BP) when standing.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05947136
Sponsor: Centre Leon Berard (Academic / non-profit / other)
Intervention(s): Interpretation Of The Results From The Detection Visit, Explaining Detection Results And Referrals To The Patient, Early Medical Care Through The Network
Start: Jan 2024  |  Primary completion: Jun 2028  |  Enrollment: 204 (estimated)
Record last updated: Jun 2026

This is a prospective, multicentre, phase III, randomised, controlled intervention study. Two groups of patients with equal numbers will be studied and each patient will be allocated to one of the two groups described below by randomisation (ratio 1:1).

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT07579026
Sponsor: Riphah International University (Academic / non-profit / other)
Start: Aug 2025  |  Primary completion: Sep 2026  |  Enrollment: 44 (estimated)
Record last updated: May 2026

Postural orthostatic tachycardia POTS is characterized by excessive increase in heart rate when moving from lying to standing position, often accompanied by symptoms such as dizziness, fatigue, brain fog, lightheadedness, rapid heartbeat and palpitation.it most commonly effects the females of reproductive age and can be triggered by events like viral infections, trauma and hormonal changes.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05924646
Sponsor: University of Calgary (Academic / non-profit / other)
Intervention(s): Microcystalline Cellulose Capsules
Start: May 2024  |  Primary completion: Jun 2028  |  Enrollment: 50 (estimated)
Record last updated: May 2026

Many patients with postural orthostatic tachycardia syndrome (POTS) have decreased plasma volume. Current POTS guidelines recommend \~10 g of salt and 2-3 L of fluid per day. Despite this recommendation, there is no long term data evaluating the use of salt in POTS.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05914649
Sponsor: University of Calgary (Academic / non-profit / other)
Intervention(s): Iv Normal Saline
Start: Sep 2024  |  Primary completion: Dec 2030  |  Enrollment: 100 (estimated)
Record last updated: May 2026

Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Post-Acute Sequelae of COVID (PASC, or "Long COVID") experience cognitive dysfunction. The investigators will test the hypothesis that 999 mL of IV saline will improve cognitive function in patients with POTS and Long COVID compared to placebo (50 mL of saline).

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT04881318
Sponsor: University of Calgary (Academic / non-profit / other)
Intervention(s): Waist-High Compression Tights, Abdominal Compression Garments, Medications That Modulate Heart Rate And Blood Pressure
Start: May 2021  |  Primary completion: Dec 2026  |  Enrollment: 30 (estimated)
Record last updated: May 2026

Compression Garments are a commonly prescribed treatment in Postural Orthostatic Tachycardia Syndrome (POTS). The effectiveness of a proof-of-concept compression garment has been demonstrated in an acute laboratory setting. It is not known if commercially available compression garments that participants wear in their every day lives are effective at improving heart rate and reducing symptoms in POTS.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT04271878
Sponsor: University of Calgary (Academic / non-profit / other)
Intervention(s): Respiract™ System
Start: Feb 2022  |  Primary completion: Dec 2029  |  Enrollment: 26 (estimated)
Record last updated: May 2026

The mechanism behind postural orthostatic tachycardia syndrome (POTS) involves many causes including a sympathetic nervous system problem. Blood gases, like carbon dioxide (CO2), have an important effect on sympathetic activation. The purpose of this research study is to determine if higher CO2 levels have any effect in lowering heart rate and reducing POTS symptoms when upright/standing.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05633693
Sponsor: Simon Fraser University (Academic / non-profit / other)
Intervention(s): Counterpressure Maneuvers, Baseline Stand
Start: Apr 2023  |  Primary completion: May 2027  |  Enrollment: 30 (estimated)
Record last updated: Apr 2026

The investigators are interested in whether discrete counterpressure maneuvers, or muscle movements in the lower body, will boost blood pressure and cardiovascular control in children who faint.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05555771
Sponsor: Dr. Victoria Claydon (Academic / non-profit / other)
Intervention(s): Counterpressure Maneuvers
Start: Sep 2022  |  Primary completion: Sep 2027  |  Enrollment: 300 (estimated)
Record last updated: Apr 2026

The investigators will assess the efficacy of clinically recommended counterpressure maneuvers (CPM) in preventing syncope for paediatric patients. Participants presenting to the emergency department (ED) will first provide written informed consent. In stage I, they will be asked to complete a brief survey documenting the presentation of their syncopal episode, and any prodromal symptoms they experienced.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05618054
Sponsor: Virginia Commonwealth University (Academic / non-profit / other)
Intervention(s): Looming Task
Start: Mar 2023  |  Primary completion: Dec 2026  |  Enrollment: 36 (estimated)
Record last updated: Apr 2026

This study is being conducted to see how people with Postural tachycardia syndrome (POTS) make sense of the things they see. The information may help doctors to learn more about how the different parts of people's brains communicate.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05748015
Sponsor: Istituti Clinici Scientifici Maugeri SpA (Academic / non-profit / other)
Intervention(s): Quantification Of Sensory And Autonomic Small Nerve Fibers By Punch Skin Biopsy, Cardiovascular Reflexes Testing, Administration Of Clinical Scales Evaluating Autonomic Symptoms, Pain Small Fiber Neuropathy Symptoms
Start: Mar 2021  |  Primary completion: Nov 2026  |  Enrollment: 60 (estimated)
Record last updated: Apr 2026

The goal of this interventional non-pharmacological study is to evaluate the involvement of the autonomic nervous system in patients with relapsing-remitting and primary progressive multiple sclerosis.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06292377
Sponsor: Brugmann University Hospital (Academic / non-profit / other)
Intervention(s): Ecg, Transthoracic Echography, Blood Sampling
Start: Jun 2024  |  Primary completion: Dec 2027  |  Enrollment: 250 (estimated)
Record last updated: Mar 2026

Stroke is worldwide the second most common cause of death following heart attack and the leading cause of disability. Post-stroke fatigue (PSF) is a common complication after stroke and can be defined as 'an overwhelming exhaustion or tiredness, not related to exertion, which does not typically improve with rest'. Fatigue following stroke can be divided into early (\< 3 months) and late (\> 3 months) fatigue.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT01912313
Sponsor: KU Leuven (Academic / non-profit / other)
Intervention(s): Rectal Biopsies From Ibs Patients Or Healthy Subjects Will Be Taken During Proctoscopy
Start: Aug 2013  |  Primary completion: Dec 2026  |  Enrollment: 99999999 (estimated)
Record last updated: Mar 2026

Rectal biopsies from IBS patients or healthy subjects will be taken.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT07478172
Sponsor: University of Missouri-Columbia (Academic / non-profit / other)
Intervention(s): Whole-Body Electrical Muscle Stimulation Exercise
Start: Mar 2026  |  Primary completion: Dec 2030  |  Enrollment: 50 (estimated)
Record last updated: Mar 2026

This single-arm pilot study evaluates the effects of whole-body electrical muscle stimulation (WB-EMS) exercise on neuromuscular and physical function in adults with neuromuscular disease (NMD). Due to motor unit impairments, NMD patients often cannot tolerate traditional exercise. WB-EMS bypasses voluntary activation limits by directly stimulating muscle contractions.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT07455994
Sponsor: Centre Hospitalier Universitaire de Saint Etienne (Academic / non-profit / other)
Intervention(s): Neurocoach® And Sudoscan®
Start: Dec 2025  |  Primary completion: Dec 2026  |  Enrollment: 100 (estimated)
Record last updated: Mar 2026

Some physiological factors, such as physical activity, or pathological factors, such as sepsis or diabetes, are known to modulate the overall autonomic activity and the individual's intrinsic capacity to regulate their sympathetic and parasympathetic balance.

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT00409435
Sponsor: Mayo Clinic (Academic / non-profit / other)
Intervention(s): Pyridostigmine
Start: Oct 2006  |  Primary completion: Feb 2027  |  Enrollment: 50 (estimated)
Record last updated: Mar 2026

This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT06073886
Sponsor: University of California, Los Angeles (Academic / non-profit / other)
Intervention(s): Active Ctbs, Imaginal Exposure
Start: Mar 2024  |  Primary completion: Jul 2026  |  Enrollment: 75 (estimated)
Record last updated: Feb 2026

The goal of this study is to investigate a new treatment for chronic symptoms after concussion or mild traumatic brain injury in people aged 18-65 years old. Chronic symptoms could include dizziness, headache, fatigue, brain fog, memory difficulty, sleep disruption, irritability, or anxiety that occurred or worsened after the injury.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06863207
Sponsor: Medical College of Wisconsin (Academic / non-profit / other)
Intervention(s): Percutaneous Electrical Nerve Field Stimulation, Hypnotherapy
Start: Jan 2025  |  Primary completion: Dec 2028  |  Enrollment: 120 (estimated)
Record last updated: Feb 2026

Disorders of gut-brain interaction (DGBI) affect up to 25% of U.S. children. Patients often suffer from disabling, multisystem comorbidities that suggest a common root (sleep disturbances, fatigue, anxiety, etc). Yet, DGBI are defined and treated based on GI symptom origin (cyclic vomiting, dyspepsia, irritable bowel) rather than underlying pathophysiology.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05212129
Sponsor: Medical College of Wisconsin (Academic / non-profit / other)
Intervention(s): Percutaneous Vagal Nerve Stimulation (Pvns) Device, Acoustic Vagal Nerve Stimulation (Avns) Treatment
Start: Apr 2021  |  Primary completion: Dec 2026  |  Enrollment: 90 (estimated)
Record last updated: Feb 2026

Hypermobile Ehlers-Danlos Syndrome (hEDS) is a connective tissue disorder characterized by hyperextensible skin, joint hypermobility and additional connective tissue manifestations. For unclear reasons, hEDS is associated with many gastrointestinal (GI) and autonomic nervous system (ANS) complaints such as postural orthostatic tachycardia syndrome (POTS).

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT07197905
Sponsor: Vanderbilt University Medical Center (Academic / non-profit / other)
Intervention(s): Intravenous Iron
Start: Nov 2025  |  Primary completion: Oct 2026  |  Enrollment: 12 (estimated)
Record last updated: Dec 2025

People with postural orthostatic tachycardia syndrome (POTS) often have low red blood cell volumes and low ferritin in their blood (a marker of iron storage in the body). The purpose of this pilot study is to investigate whether giving iron to people with POTS who have low ferritin levels will increase the red blood cell volume and improve POTS symptoms.

View on ClinicalTrials.gov ↗
RecruitingPhase 4 NCT06695910
Sponsor: Samuel Fortin (Industry)
Intervention(s): Monoglyceride Eicosapentaenoic Acid, Sunflower Oil
Start: Nov 2024  |  Primary completion: May 2027  |  Enrollment: 48 (estimated)
Record last updated: Dec 2025

A growing body of studies shows that omega-3s act directly in molecular signaling pathways that reduce inflammation and are thought to have a positive effect on cognitive health. Brain fog is a term that has been popularized in the medical world in the wake of the COVID-19 pandemic. A significant proportion of patients with long COVID reported having cognitive sequelae that were like fogginess.

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT05375968
Sponsor: Vanderbilt University Medical Center (Academic / non-profit / other)
Intervention(s): Compare Change Is Svc And Sma Flow Due To Gip Antagonist Gip(3-30)Nh2, Compare Change Is Svc And Sma Flow Due To Saline
Start: Feb 2023  |  Primary completion: May 2027  |  Enrollment: 50 (estimated)
Record last updated: Dec 2025

Postural tachycardia syndrome (POTS) affects ≈3 million young people, characterized by chronic presyncopal symptoms characterized by dizziness, lightheadedness, and orthostatic tachycardia that occur while standing.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT07019519
Sponsor: University of Copenhagen (Academic / non-profit / other)
Intervention(s): Gipr Antagonist, Glp-1R Antagonist, Cck Agonist
Start: Mar 2025  |  Primary completion: Jun 2026  |  Enrollment: 30 (estimated)
Record last updated: Jun 2025

This study will describe the interplay between the gut hormones GIP and CCK and their regulation of blood flow to the large vessels in patients with Postural Orthostatic Tachycardia Syndrome (POTS) and GIP, CCK and GLP-1 in healthy. This is addressed by hormone infusions during MR-scans of the abdomen and intake of oral glucose.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06936319
Sponsor: Medical University Innsbruck (Academic / non-profit / other)
Intervention(s): Best Clinical Practice Plus Cpm-Biofeedback Training, Best Clinical Practice
Start: Jan 2025  |  Primary completion: Dec 2025  |  Enrollment: 40 (estimated)
Record last updated: May 2025

The present study evaluates whether performing a 14-days counter pressure maneuvers (CPM)-biofeedback training improves the symptomatic burden (primary objective) and secondarily the interference of POTS symptoms with daily activities, fatigue, and health-related quality of life of individuals with POTS compared to best clinical practice non-pharmacological measures.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06817707
Sponsor: Centre Hospitalier Universitaire de Nice (Academic / non-profit / other)
Intervention(s): Evaluation Of Urinary Dysfunction In Patients With Canvas
Start: Mar 2025  |  Primary completion: Mar 2027  |  Enrollment: 40 (estimated)
Record last updated: Mar 2025

The investigator wishes to evaluate the prevalence of urinary symptoms in patients diagnosed with Cerebellar Ataxia, Neuropathy, Vestibular Areflexia Syndrome (CANVAS). As much as one third of patients living with CANVAS experience symptoms of urinary system dysfunction.

View on ClinicalTrials.gov ↗
RecruitingPhase 4 NCT06792214
Sponsor: Mount Sinai Hospital, Canada (Academic / non-profit / other)
Start: Jan 2025  |  Primary completion: Jan 2026  |  Enrollment: 118 (estimated)
Record last updated: Jan 2025

The DEFEND trial will be the world's first clinical trial to study the effectiveness of Paxlovid or Veklury in the prevention of cardiovascular post-acute sequelae of SARS-CoV-2 among hospitalized adults. Additionally, this pilot study will inform the design and conduct of a future full-scale multi-centre trial by testing the feasibility and accuracy of this study design.

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT04186286
Sponsor: University of Calgary (Academic / non-profit / other)
Intervention(s): Ivabradine 4-Week Course, Propranolol 4-Week Course
Start: Feb 2021  |  Primary completion: Dec 2025  |  Enrollment: 20 (estimated)
Record last updated: May 2024

1.0 BACKGROUND Postural tachycardia syndrome (POTS) is a disorder of chronic orthostatic intolerance characterized by symptoms of palpitations, lightheadedness, chest discomfort, shortness of breath, blurred vision, and mental clouding. These symptoms occur during standing and are associated with a marked increase in heart rate (HR) in the absence of hypotension, which typically resolve when sitting or lying down.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT04151693
Sponsor: Joint Authority for Päijät-Häme Social and Health Care (Academic / non-profit / other)
Intervention(s): Health Psychological Group Rehabilitation For Patients With Chronic Fatigue Syndrome
Start: Nov 2019  |  Primary completion: May 2028  |  Enrollment: 80 (estimated)
Record last updated: Apr 2024

Chronic fatigue syndrome (ME/CFS) is a severe medical condition. It is characterized by long term fatique and other persisted symptoms, such as a cognitive disabilities and orthostatic intolerance. Symptoms limit a persons ability to carry out ordinary daily activities.

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT06012552
Sponsor: Military Institute od Medicine National Research Institute (Academic / non-profit / other)
Intervention(s): Tianeptine
Start: Feb 2023  |  Primary completion: Apr 2027  |  Enrollment: 140 (estimated)
Record last updated: Aug 2023

COVID-19 is associated with a high risk of complications from the central nervous system. Syndrome of cognitive disorders- in terms of memory, attention or executive functions among COVID-19 convalescents is often called brain fog (covid fog - CF). CF leads to psychomotor retardation and chronic fatigue syndrome, resulting in poor functioning and low quality of life.

View on ClinicalTrials.gov ↗

Not yet recruiting (16)

Not yet recruitingPhase not applicable NCT07842302
Sponsor: Universitat Oberta de Catalunya (Academic / non-profit / other)
Intervention(s): Tms, Tdcs
Start: Sep 2026  |  Primary completion: May 2029  |  Enrollment: 80 (estimated)
Record last updated: Sep 2026

Multiple Sclerosis (MS) is a chronic neurological disease impacting 2.8 million individuals globally, with fatigue being its most debilitating symptom, reported by 75% of patients. Despite its prevalence, the pathophysiology of MS-related fatigue remains poorly understood, and current pharmacological treatments have limited effectiveness.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT07837804
Sponsor: University Medical Centre Ljubljana (Academic / non-profit / other)
Intervention(s): Bilateral Sequential Stellate Ganglion Block
Start: Oct 2026  |  Primary completion: Oct 2027  |  Enrollment: 30 (estimated)
Record last updated: Sep 2026

RESET-POTS is a pilot study for adults with postural orthostatic tachycardia syndrome (POTS), a condition that can cause a rapid increase in heart rate, dizziness, weakness, fatigue and other symptoms when standing. The study has two parts.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT05618067
Sponsor: Virginia Commonwealth University (Academic / non-profit / other)
Intervention(s): Breathing Exercise Training
Start: Jan 2028  |  Primary completion: Dec 2028  |  Enrollment: 12 (estimated)
Record last updated: Sep 2026

This study is being to see if participating in breathing exercise training and practicing this training will help with Postural tachycardia syndrome (POTS). The information may help doctors to learn more about how the different parts of people's brains communicate.

View on ClinicalTrials.gov ↗
Not yet recruitingEarly Phase 1 NCT07757555
Sponsor: Johns Hopkins University (Academic / non-profit / other)
Intervention(s): Guanfacine, Cromolyn Sodium
Start: Aug 2026  |  Primary completion: Dec 2027  |  Enrollment: 25 (estimated)
Record last updated: Aug 2026

The goal of this clinical trial is to learn whether guanfacine or cromolyn sodium can improve symptoms and physical functioning in adults with Postural Orthostatic Tachycardia Syndrome (POTS). Both medications are FDA-approved for other conditions but are investigational for the treatment of POTS.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase 1 NCT07675876
Sponsor: Carcinex Inc (Industry)
Intervention(s): Cromolyn Sodium
Start: Aug 2026  |  Primary completion: Jun 2027  |  Enrollment: 10 (estimated)
Record last updated: Jul 2026

This prospective, open-label pilot study is designed to evaluate the safety, tolerability, feasibility, and preliminary clinical activity of inhaled cromolyn sodium administered by dry powder inhalation in participants with locally advanced lung cancer. Cromolyn sodium is an FDA-approved mast cell stabilizer with an established safety profile in respiratory disease.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT07600320
Sponsor: Icahn School of Medicine at Mount Sinai (Academic / non-profit / other)
Intervention(s): Fareon Device
Start: May 2026  |  Primary completion: Apr 2027  |  Enrollment: 30 (estimated)
Record last updated: May 2026

The purpose of this study is to assess the safety and feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to acquired brain injury, Long COVID, traumatic brain injury, myalgic encephalomyelitis (ME/CFS), and other neurodegenerative diagnoses including but not limited to Alzheimer's disease and to collect data on safety and efficacy to inform the design of larger clinical studies.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase 2 NCT07585513
Sponsor: Cedars-Sinai Medical Center (Academic / non-profit / other)
Intervention(s): Mirabegron
Start: May 2026  |  Primary completion: May 2028  |  Enrollment: 36 (estimated)
Record last updated: May 2026

The study will test the hypothesis that mirabegron is more effective than a placebo in alleviating postural orthostatic tachycardia (POTS) symptoms.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT07409363
Sponsor: University of Leeds (Academic / non-profit / other)
Intervention(s): Active Vagus Nerve Stimulation
Start: May 2026  |  Primary completion: Jul 2026  |  Enrollment: 12 (estimated)
Record last updated: May 2026

Chronic musculoskeletal (MSK) pain affects an estimated 20-33% of the global population and is frequently associated with autonomic nervous system dysfunction, characterised by symptoms such as orthostatic intolerance, palpitations, gastrointestinal dysmotility, and fatigue. Conventional treatments often fail to address this autonomic component, limiting their effectiveness.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase 4 NCT05363514
Sponsor: University of Calgary (Academic / non-profit / other)
Intervention(s): Low Dose Naltrexone, Microcrystalline Cellulose
Start: Jul 2026  |  Primary completion: Jun 2029  |  Enrollment: 80 (estimated)
Record last updated: May 2026

Many patients with Postural Orthostatic Tachycardia Syndrome (POTS) experience debilitating fatigue and this significantly impacts their daily lives. Unfortunately, there are no treatments to help POTS patients with their fatigue. One medication, called low dose naltrexone (LDN), has been tested as a treatment for fatigue in other medical conditions.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase 2 NCT07526558
Sponsor: University of North Carolina, Chapel Hill (Academic / non-profit / other)
Intervention(s): Ketotifen, Fexofenadine, Cromolyn Sodium
Start: Apr 2026  |  Primary completion: Jan 2027  |  Enrollment: 50 (estimated)
Record last updated: Apr 2026

This is a Phase II double-blinded study to assess the safety, tolerability, and feasibility of the mast cell stabilizing medications ketotifen and cromolyn compared to participants receiving standard of care treatment with fexofenadine alone in participants who have persistent symptoms of mast cell activation following a documented tick-borne illness (Ehrlichiosis, Rocky Mountain Spotted Fever, Alpha-gal Syndrome).

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT07259902
Sponsor: University of Milan (Academic / non-profit / other)
Intervention(s): Fmri
Start: Jan 2026  |  Primary completion: Jan 2030  |  Enrollment: 60 (estimated)
Record last updated: Dec 2025

Temporomandibular disorders (TMD) are among the most common causes of chronic pain worldwide. It is estimated that about 5-12% of the global population is affected, and some conditions, such as arthritis, may be causative factors. Depending on severity, the joints involved can affect multiple functions of the masticatory system, such as the ability to speak, chew, swallow, limit facial expressions, and even breathe.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT06953661
Sponsor: Stanford University (Academic / non-profit / other)
Intervention(s): Stellate Ganglion Block, Ropivacaine, Normal Saline
Start: Oct 2025  |  Primary completion: Nov 2026  |  Enrollment: 20 (estimated)
Record last updated: Oct 2025

This single-center study aims to evaluate both immediate and long-term outcomes of stellate ganglion block (SGB) in a cohort of rigorously phenotyped patients with Postural Tachycardia Syndrome (POTS). By assessing the effects of SGB, this study seeks to determine its viability as an intervention for symptom control in POTS.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT07163130
Sponsor: Aristotle University Of Thessaloniki (Academic / non-profit / other)
Intervention(s): Transcutaneous Auricular Vagus Nerve Stimulation
Start: Sep 2025  |  Primary completion: Dec 2026  |  Enrollment: 24 (estimated)
Record last updated: Sep 2025

Postural Tachycardia Syndrome (POTS) is a form of dysautonomia characterized by an abnormal cardiovascular response to orthostatic challenges. Individuals afflicted with POTS typically exhibit a heart rate increase of more than 30 beats per minute (bpm) within 10 minutes of assuming an upright posture from a supine or sitting position.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase 2 NCT07089719
Sponsor: Assistance Publique - Hôpitaux de Paris (Academic / non-profit / other)
Intervention(s): Bevacizumab Injection
Start: Oct 2025  |  Primary completion: Jan 2028  |  Enrollment: 21 (estimated)
Record last updated: Jul 2025

The aim of this research is to evaluate an innovative treatment, Bevacizumab, in patients suffering from respiratory complications related to COVID-19. These complications, particularly difficulty breathing (dyspnea) and impaired lung function, are common in some individuals after infection.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase 4 NCT07077278
Sponsor: Stanford University (Academic / non-profit / other)
Intervention(s): Low Sodium Oxybate
Start: Oct 2025  |  Primary completion: Sep 2027  |  Enrollment: 25 (estimated)
Record last updated: Jul 2025

The investigators hope to learn if low sodium oxybate (LXB) is an effective treatment for symptoms of idiopathic hypersomnia (IH) and postural tachycardia syndrome (POTS). Previous research has shown that patients with IH also report having symptoms associated with POTS. The researchers have observed that in patients with both IH and POTS, when patients' sleep quality improves, so do their POTS symptoms.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT05796154
Sponsor: University of Calgary (Academic / non-profit / other)
Intervention(s): Ear Blood Pressure Monitor
Start: Jun 2025  |  Primary completion: Dec 2025  |  Enrollment: 30 (estimated)
Record last updated: Dec 2024

the investigators propose studies of a tiny, wearable, wireless, beat-to-beat blood pressure monitor that will be both a transformative research platform and an enabler of patient self-care in the diagnosis, investigation, and management of POTS.

View on ClinicalTrials.gov ↗

Enrolling by invitation (5)

Enrolling by invitationPhase 2 NCT05350774
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) (NIH)
Intervention(s): Iv Normal Saline, Iv Immunoglobulin
Start: Jul 2023  |  Primary completion: Dec 2026  |  Enrollment: 45 (estimated)
Record last updated: Aug 2026

COVID-19 can cause problems in different parts of the body. For most people, it causes fevers or trouble breathing. Some people might not recover all the way.

View on ClinicalTrials.gov ↗
Enrolling by invitationPhase 2 NCT07567274
Sponsor: Leading Edge Clinic (Academic / non-profit / other)
Intervention(s): Dmso-Based Otic Solution With Betahistine, Dexamethasone, And Lidocaine, N-Acetylcysteine (NAC)
Start: May 2026  |  Primary completion: Jul 2026  |  Enrollment: 20 (estimated)
Record last updated: May 2026

The goal of this clinical trial is to test a compounded dimethyl sulfoxide (DMSO)-based dual-route therapy for adults with refractory subjective tinnitus linked to long-COVID (post-acute sequelae of SARS-CoV-2) or post-COVID-19 vaccine injury. Participants have bothersome tinnitus that has not improved with at least two prior standard treatments.

View on ClinicalTrials.gov ↗
Enrolling by invitationPhase 2 NCT06148311
Sponsor: NYU Langone Health (Academic / non-profit / other)
Intervention(s): Dexmedetomidine
Start: Jul 2024  |  Primary completion: Jan 2027  |  Enrollment: 15 (estimated)
Record last updated: Apr 2026

The purpose of this placebo controlled interventional study is to collect preliminary data on administering dexmedetomidine in patients with Familial Dysautonomia (FD) during a rapid cessation of autonomic crisis. The primary aims are to assess the feasibility and evaluate if measurements of heart rate, blood pressure and oxygen saturation can predict the start of an autonomic crisis. Funding Source- FDA OOPD.

View on ClinicalTrials.gov ↗
Enrolling by invitationPhase not applicable NCT07320937
Sponsor: ShuGuang Hospital (Academic / non-profit / other)
Intervention(s): "Yiqi Fuyuan Paste Formula" Test Group
Start: Dec 2025  |  Primary completion: Aug 2026  |  Enrollment: 80 (estimated)
Record last updated: Jan 2026

The goal of this clinical trial is to learn if "Yiqi Fuyuan Paste Formula" (a traditional Chinese medicinal paste made from medicinal and edible Chinese medicines and health food like Ginseng Radix et Rhizoma, Astragali Radix et Rhizoma, Codonopsis Radix, Atractylodis Macrocephalae Rhizoma, Poria Cocos, Coicis Semen, Dioscoreae Rhizoma, Nelumbinis Semen, Angelicae Sinensis Radix, Lycii Fructus, Citri Reticulatae Pericarpium, Juglandis Semen, Longan Arillus, Sesami Nigri Semen, Jujubae Fructus, Glycyrrhizae Radix…

View on ClinicalTrials.gov ↗
Enrolling by invitationPhase not applicable NCT02725060
Sponsor: Vanderbilt University Medical Center (Academic / non-profit / other)
Intervention(s): Phenylephrine, Isoproterenol, 25 Micro-Ci Of Radiation, 24-Hour Heart Rhythm And Blood Pressure Monitoring, Quantitative Axonal Sudomotor Reflex Testing, Autonomic Function Tests, Rebreathing Test, Assessment Of Splanchnic Capacitance, Microneurography
Start: Feb 2016  |  Primary completion: Oct 2026  |  Enrollment: 58 (estimated)
Record last updated: Nov 2025

The purpose of this study is to see if some people with postural tachycardia syndrome (POTS) have higher levels of immune proteins (autoantibodies) directed against receptors of the autonomic nervous system, and if these autoantibodies make a difference in their POTS symptoms. The investigators also want to see if the levels of these autoantibodies stay the same over time.

View on ClinicalTrials.gov ↗

Active, not recruiting (12)

Active, not recruitingPhase not applicable NCT04137757
Sponsor: Milton S. Hershey Medical Center (Academic / non-profit / other)
Intervention(s): Lower Body Negative Pressure
Start: Feb 2022  |  Primary completion: Dec 2027  |  Enrollment: 21 (actual)
Record last updated: Sep 2026

Postural tachycardia syndrome (POTS) is one of the most common forms of chronic orthostatic intolerance in the United States. This is a disabling disorder characterized by an excessive increase in heart rate upon standing that is accompanied by symptoms such as dizziness and fatigue.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase 1 NCT03124355
Sponsor: Vanderbilt University Medical Center (Academic / non-profit / other)
Intervention(s): Pyridostigmine Pill, Galantamine Pill, Vagal Stimulation
Start: Sep 2017  |  Primary completion: Jun 2027  |  Enrollment: 11 (actual)
Record last updated: Jul 2026

The purpose of this study is to investigate how the electrical stimulation of a nerve in the skin of the earlobe (transcutaneous vagal nerve stimulation), alone or in combination with two medications (galantamine and pyridostigmine), affects the way the autonomic (involuntary) nervous system controls heart rhythm, symptoms on standing, and inflammatory markers in female patients with postural tachycardia syndrome (POTS).

View on ClinicalTrials.gov ↗
Active, not recruitingEarly Phase 1 NCT04140721
Sponsor: Vanderbilt University Medical Center (Academic / non-profit / other)
Intervention(s): Moxonidine Pill
Start: Aug 2021  |  Primary completion: Dec 2025  |  Enrollment: 48 (estimated)
Record last updated: Mar 2026

Postural tachycardia syndrome (POTS) is a relatively common condition affecting mostly otherwise healthy young women. These patients have high heart rate and disabling symptoms during standing. Quality of life may be poor.

View on ClinicalTrials.gov ↗
Active, not recruitingEarly Phase 1 NCT04050410
Sponsor: Vanderbilt University Medical Center (Academic / non-profit / other)
Intervention(s): Moxonidine
Start: Aug 2019  |  Primary completion: Dec 2025  |  Enrollment: 48 (estimated)
Record last updated: Mar 2026

Postural tachycardia syndrome (POTS) is a relatively common condition affecting mostly otherwise healthy young women. It is the cause of significant disability and an impairment in quality of life. These patients have high heart rate and symptoms during standing.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase not applicable NCT02281097
Sponsor: Vanderbilt University (Academic / non-profit / other)
Intervention(s): Stimulation
Start: Jun 2013  |  Primary completion: Apr 2017  |  Enrollment: 18 (actual)
Record last updated: Mar 2026

Some patients experience high heart rates and symptoms of light-headedness, fatigue, headache during standing despite well maintained blood pressure. These patient are disabled and can't be in upright position for a longer time. The purpose of this study is to test whether electrical stimulation of a nerve through a skin of the ear may improve heart rate response and reduce disabling symptoms.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase 2 NCT06128356
Sponsor: NYU Langone Health (Academic / non-profit / other)
Intervention(s): Dexmedetomidine Sublingual
Start: Jun 2024  |  Primary completion: Sep 2028  |  Enrollment: 5 (actual)
Record last updated: Mar 2026

This is a pilot open-label study to evaluate the feasibility of conducting a clinical trial using sublingual dexmedetomidine sublingual film to treat hyperadrenergic autonomic crises in patients with Familial Dysautonomia at home.

View on ClinicalTrials.gov ↗
Active, not recruitingEarly Phase 1 NCT01988883
Sponsor: Vanderbilt University Medical Center (Academic / non-profit / other)
Intervention(s): Modafinil, Propranolol
Start: Oct 2014  |  Primary completion: Dec 2026  |  Enrollment: 20 (actual)
Record last updated: Jan 2026

A common complaint among patients with Postural Tachycardia Syndrome (POTS) is "brain fog" or difficulty concentrating. This problem is poorly understood. The purpose of this study is to better understand the cognitive dysfunction associated POTS, and to determine optimal treatment strategies for this condition.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase not applicable NCT01783288
Sponsor: Vanderbilt University (Academic / non-profit / other)
Intervention(s): Autonomic Function Testing, Posture Study, Measurement Of Total Blood Volume, Exercise Capacity Test
Start: Feb 2013  |  Primary completion: Dec 2026  |  Enrollment: 110 (estimated)
Record last updated: Jan 2026

The purpose of the study is to determine whether patients meet criteria for Postural Tachycardia Syndrome (or not) and have reduced blood volume (or not). Both of these are important screening elements to Aim 3 of a National Institutes of Health Grant.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase not applicable NCT00962728
Sponsor: Alfredo Gamboa (Academic / non-profit / other)
Intervention(s): Inspiratory Threshold Device
Start: Jul 2009  |  Primary completion: Nov 2026  |  Enrollment: 30 (estimated)
Record last updated: Dec 2025

The investigators will test whether breathing through an inspiratory resistance device will improve the ability to be upright and decrease heart rate increases on standing in patients with postural tachycardia syndrome.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase not applicable NCT01000350
Sponsor: Vanderbilt University Medical Center (Academic / non-profit / other)
Intervention(s): Saline
Start: Oct 2009  |  Primary completion: Jun 2028  |  Enrollment: 40 (estimated)
Record last updated: Oct 2025

The investigators will test whether an intravenous infusion of saline (salt water) will improve the exercise capacity in patients with postural tachycardia syndrome (POTS).

View on ClinicalTrials.gov ↗
Active, not recruitingPhase not applicable NCT00608725
Sponsor: Satish R. Raj (Academic / non-profit / other)
Intervention(s): Daxor, Qsweat, Intrinsic Heart Rate
Start: Dec 1996  |  Primary completion: Dec 2029  |  Enrollment: 260 (actual)
Record last updated: Oct 2025

The purpose of this study is to describe the mechanism of orthostatic intolerance, relying on cardiovascular physiological studies.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase 3 NCT04904536
Sponsor: The George Institute (Academic / non-profit / other)
Intervention(s): Atorvastatin
Start: Mar 2022  |  Primary completion: Jun 2025  |  Enrollment: 190 (actual)
Record last updated: Apr 2025

STRONGER is an international, investigator initiated and conducted, pragmatic clinical trial to determine whether 40mg atorvastatin daily can improve neurocognitive function in adults with long COVID neurological symptoms.

View on ClinicalTrials.gov ↗

Completed (62)

CompletedPhase not applicable NCT06517706
Sponsor: University of Cyprus (Academic / non-profit / other)
Intervention(s): Combination Of Tdcs, Categorization Program
Start: Nov 2024  |  Primary completion: Jun 2026  |  Enrollment: 38 (actual)
Record last updated: Sep 2026

The aim of the experimental study is to investigate two interventions for the management of cognitive symptoms resulting from long COVID. Participants will be randomly assigned into two interventions. 1.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05043051
Sponsor: University of Oklahoma (Academic / non-profit / other)
Intervention(s): Vagal Stimulation
Start: Jan 2022  |  Primary completion: Feb 2026  |  Enrollment: 80 (actual)
Record last updated: Jul 2026

The purpose of this study is to test the hypothesis that an antibody-mediated autoimmune reaction will cause symptoms of autonomic dysfunction in some patients with postural tachycardia syndrome (POTS). The investigators further hypothesize that electrical stimulation of the vagus nerve will improve POTS symptoms, autoimmunity and inflammation.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT06593600
Sponsor: Regeneron Pharmaceuticals (Industry)
Intervention(s): Regn7544
Start: Nov 2024  |  Primary completion: May 2026  |  Enrollment: 82 (actual)
Record last updated: Jul 2026

This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on participants with POTS. The aim of the study is to see how safe, tolerable, and effective the study drug is.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT04827992
Sponsor: Massachusetts General Hospital (Academic / non-profit / other)
Intervention(s): Cannabis, Prescription Opioid Taper Support
Start: Aug 2021  |  Primary completion: May 2025  |  Enrollment: 87 (actual)
Record last updated: Jun 2026

This study will use a randomized controlled design to test whether medical marijuana use by adults on high-dose chronic opioid therapy (COT) for chronic non-cancer pain is associated with reduced opioid dose and improved pain intensity and interference when added to a 24-week behavioral intervention (POTS).

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06208163
Sponsor: Life University (Academic / non-profit / other)
Intervention(s): Chiropractic
Start: Nov 2024  |  Primary completion: Sep 2025  |  Enrollment: 18 (actual)
Record last updated: May 2026

Since 1980, the global prevalence of obesity, commonly defined as a body mass index (BMI) of 30 or higher, has doubled. Importantly, high levels of central adiposity (i.e., abdominal fat) is associated with numerous PNI-related sequelae, including increased levels of psychological distress, cognitive deficits, ANS dysfunction, and immune marker abnormalities.

View on ClinicalTrials.gov ↗
CompletedPhase 1 NCT04977388
Sponsor: Stephen G. Kaler, MD (Academic / non-profit / other)
Intervention(s): Droxidopa
Start: Jul 2021  |  Primary completion: Oct 2023  |  Enrollment: 3 (actual)
Record last updated: Apr 2026

The purpose of this study is to evaluate whether Northera (Droxidopa) is safe and effective in young adults with Menkes disease who survived the most severe complications of their illness or adults with occipital horn syndrome (OHS), who have trouble with intermittent low blood pressure and other symptoms of dysautonomia.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT06133075
Sponsor: Cedars-Sinai Medical Center (Academic / non-profit / other)
Intervention(s): Mirabegron 50 Mg, Mirabegron 25 Mg
Start: Dec 2023  |  Primary completion: May 2025  |  Enrollment: 20 (actual)
Record last updated: Apr 2026

This is a pilot dose-finding study to test the hypothesis that mirabegron increases systolic blood pressure (BP), prevents syncope/presyncope, and improves the quality of life (QOL), functional capacity, chest pain, and overactive bladder (OAB) symptoms in patients with postural orthostatic tachycardia syndrome (POTS) who have a documented history of hypotension inadequately responsive to conventional treatments.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT07182578
Sponsor: California State University, Dominguez Hills (Academic / non-profit / other)
Intervention(s): Aquatic Occupational Therapy
Start: Sep 2025  |  Primary completion: Feb 2026  |  Enrollment: 5 (actual)
Record last updated: Apr 2026

The goal of this pilot study is to create, implement, and evaluate an aquatic therapy for Postural Orthostatic Tachycardia Syndrome (POTS) program feasibility and ability to improve quality of life as determined by reduced orthostatic tachycardia, reduced POTS symptoms, and improved quality of life measures.

View on ClinicalTrials.gov ↗
CompletedPhase 1 NCT05445921
Sponsor: Washington University School of Medicine (Academic / non-profit / other)
Intervention(s): Stellate Ganglion Block
Start: Sep 2022  |  Primary completion: Dec 2022  |  Enrollment: 20 (actual)
Record last updated: Feb 2026

Chronic olfactory dysfunction from the COVID-19 pandemic is a growing public health crisis with up to 1.2 million people in the Unites States affected. Olfactory dysfunction impacts one's quality of life significantly by decreasing the enjoyment of foods, creating environmental safety concerns, and affecting one's ability to perform certain jobs.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT07029191
Sponsor: University Hospital, Angers (Other government)
Intervention(s): Progressive Standing Test
Start: Nov 2025  |  Primary completion: Dec 2025  |  Enrollment: 12 (actual)
Record last updated: Dec 2025

Dysautonomia is an alteration of the autonomic nervous system that manifests itself in different forms, some of which are very disabling. Dysautonomia accompanies many pathologies. Its importance in public health is illustrated by an incidence of 20-70% in diabetes.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06268288
Sponsor: Mayo Clinic (Academic / non-profit / other)
Intervention(s): Gammacore Intervention, Steps Management Protocol
Start: Feb 2024  |  Primary completion: Oct 2024  |  Enrollment: 40 (actual)
Record last updated: Oct 2025

The purpose of this study is to determine if nVNS will decrease autonomic symptom intensity (COMPASS-31 and Child Functional Disability Inventory) in adolescent patients with postural orthostatic tachycardia syndrome (POTS) in comparison to standard recovery STEPS management.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05956405
Sponsor: Hospital Miguel Servet (Academic / non-profit / other)
Intervention(s): Air + Mindfulness, Relaxation Condition
Start: Sep 2023  |  Primary completion: Mar 2024  |  Enrollment: 120 (actual)
Record last updated: Sep 2025

Prolonged COVID, also known as post-COVID or Sar-CoV-2 infection with post-acute sequelae, refers to a set of multi-organ symptoms that persist in patients who have suffered SARS-CoV-2 infection, even after of the acute phase of the disease. Approximately 10% of people experience this set of symptoms after their acute COVID has resolved.

View on ClinicalTrials.gov ↗
CompletedPhase 1 NCT00962949
Sponsor: Vanderbilt University Medical Center (Academic / non-profit / other)
Intervention(s): Angiotensin Ii
Start: Apr 2009  |  Primary completion: Dec 2012  |  Enrollment: 28 (actual)
Record last updated: Sep 2025

The purpose of this study is to determine the role of the renin-angiotensin-aldosterone in the pathophysiology of postural tachycardia syndrome, and to provide an insight about the disease process in this disorder.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT05633407
Sponsor: argenx (Industry)
Intervention(s): Efgartigimod
Start: Sep 2022  |  Primary completion: Apr 2024  |  Enrollment: 53 (actual)
Record last updated: May 2025

The study aims to investigate the safety, tolerability, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod compared to placebo in participants with post-COVID-19 postural orthostatic tachycardia syndrome (POTS) (post-COVID-19 POTS).

View on ClinicalTrials.gov ↗
CompletedEarly Phase 1 NCT01791816
Sponsor: New York Medical College (Academic / non-profit / other)
Intervention(s): Phenylephrine, L-Ng-Monomethyl Arginine
Start: Feb 2013  |  Primary completion: Dec 2022  |  Enrollment: 90 (estimated)
Record last updated: May 2025

Vasovagal Syncope (simple postural faint) is the most common cause of acute loss of consciousness. Postural tachycardia syndrome(POTS) is the most common chronic form of postural lightheadedness. Together they afflict many Americans, mostly young women, who are prevented from gainful employ or school attendance.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06575920
Sponsor: University of Agder (Academic / non-profit / other)
Intervention(s): Breathing Excercizes
Start: Oct 2023  |  Primary completion: Nov 2023  |  Enrollment: 15 (actual)
Record last updated: Apr 2025

Medically unexplained physical symptoms (MUPS) capture conditions characterized by symptoms without corresponding objective findings, such as asthenia, low back pain, fibromyalgia, irritable bowel syndrome, or chronic fatigue syndrome.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06296914
Sponsor: Jami Warren (Academic / non-profit / other)
Intervention(s): Potsapp
Start: Feb 2024  |  Primary completion: Feb 2025  |  Enrollment: 20 (actual)
Record last updated: Mar 2025

Postural Orthostatic Tachycardia Syndrome (POTS) affects approximately 500,000 - 3 million Americans. This number will only increase due to the large number of patients experiencing POTS due to "long COVID." POTS patients experience several symptoms, including tachycardia, palpitations, dizziness, and pre-syncope or syncope, among others.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT04170725
Sponsor: Insel Gruppe AG, University Hospital Bern (Academic / non-profit / other)
Intervention(s): Patient And Healthy Volunteers Training Protocol
Start: Jan 2020  |  Primary completion: Mar 2025  |  Enrollment: 15 (actual)
Record last updated: Mar 2025

POTS patients seem to experience orthostasis-dependent muscle weakness and pain as well as increased muscle fatigue upon physical activity, which can be improved by regular aerobic exercise. However, reduced sweat production of the extremities with limited control of the body temperature leads to exercise intolerance, so that sticking to a training program becomes a challenge for most patients.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05454137
Sponsor: University of Arizona (Academic / non-profit / other)
Intervention(s): Shared Medical Appointment
Start: Nov 2023  |  Primary completion: Aug 2024  |  Enrollment: 10 (actual)
Record last updated: Mar 2025

Postural orthostatic tachycardia syndrome (POTS) is a clinical syndrome encompassing a myriad of debilitating symptoms that does not have any FDA approved drug therapies. We propose a shared medical appointment intervention where participants will learn lifestyle management therapies and integrative practices that may improve quality of life.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06795750
Sponsor: Uşak University (Academic / non-profit / other)
Intervention(s): Neural Therapy, Exercise
Start: Nov 2023  |  Primary completion: Apr 2024  |  Enrollment: 60 (actual)
Record last updated: Jan 2025

Autonomic dysfunction has been observed in patients with fibromyalgia and is associated with symptoms and arrhythmia development in such patients.The investigators can analyze dysautonomia using heart rate recovery (HRR). Studies have reported that impaired HRR improves after exercise in fibromyalgia patients.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05803824
Sponsor: Cairo University (Academic / non-profit / other)
Intervention(s): Exercise Therapy Program
Start: Dec 2022  |  Primary completion: Aug 2023  |  Enrollment: 90 (actual)
Record last updated: Nov 2024

90 patients who suffer from chronic fatigue syndrome and postural imbalance following Lower Limb Burn Injury. will be selected from outpatient clinic, faculty of physical therapy, Cairo university.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT04943276
Sponsor: Stanford University (Academic / non-profit / other)
Intervention(s): Embr Device
Start: Feb 2022  |  Primary completion: Nov 2023  |  Enrollment: 23 (actual)
Record last updated: Oct 2024

The investigators hope to learn the feasibility and preliminary efficacy of the Embr device for improving thermal comfort in individuals with POTS and impaired thermoregulation. Feasibility will be assessed via usage of the Embr device and participant feedback.

View on ClinicalTrials.gov ↗
CompletedPhase 1 NCT03919773
Sponsor: University of Texas Southwestern Medical Center (Academic / non-profit / other)
Intervention(s): IVIG (Intravenous Immunoglobulin), Albumin
Start: Oct 2018  |  Primary completion: Jun 2023  |  Enrollment: 30 (actual)
Record last updated: Sep 2024

The purpose of this trial is to evaluate the symptomatic benefits of immunomodulatory treatment with IVIG for POTS (postural tachycardia syndrome) patients with evidence of autoimmunity.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06017232
Sponsor: Université de Sherbrooke (Academic / non-profit / other)
Intervention(s): Hybrid Telerehabilitation Program
Start: Jun 2023  |  Primary completion: Apr 2024  |  Enrollment: 16 (actual)
Record last updated: May 2024

People diagnosed with Parkinson's Disease (PD) exhibit a combination of motor and non-motor symptoms, with the latter posing challenges in terms of identification and management. These non-motor symptoms tend to manifest before the motor symptoms and progressively worsen over time, significantly impacting the symptoms and everyday life activities of those affected.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT03930914
Sponsor: University of Oklahoma (Academic / non-profit / other)
Intervention(s): Parasym (Tm) Transcutaneous Electrical Nerve Stimulation (Tens) Device
Start: Nov 2019  |  Primary completion: Mar 2020  |  Enrollment: 5 (actual)
Record last updated: Dec 2023

Postural orthostatic tachycardia (POTS) is characterized by abnormalities in the autonomic nervous system in the body. The autonomic nervous system controls and regulates body functions such as heart rate, breathing, digestion, and more. The investigator has shown that patients with POTS have higher cardiovascular and adrenergic activating autoantibodies (AAb), which likely changes the normal make-up of POTS.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05469477
Sponsor: University of Pennsylvania (Academic / non-profit / other)
Intervention(s): Woop, Customized Habit Tips, Raffle Financial Incentive, Shared Pot Financial Incentive, Weekly Sms Support Text, Weekly Sms Encouragement
Start: Mar 2023  |  Primary completion: Jun 2023  |  Enrollment: 1139 (actual)
Record last updated: Oct 2023

The study team is proposing to conduct a randomized controlled trial to determine the effectiveness of behavioral and financial incentives on phone use while driving and seat belt adherence. Each arm will receive a support text if their app is not collecting data.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT03681080
Sponsor: RWTH Aachen University (Academic / non-profit / other)
Intervention(s): Leg Crossing
Start: Apr 2017  |  Primary completion: May 2021  |  Enrollment: 110 (actual)
Record last updated: Jun 2023

People with POTS, autoimmune autonomic neuropathy (AAN), pure autonomic failure (PAF), SFN and Ehlers Danlos Syndrome (EDS) do not only suffer from orthostatic symptoms such as dizziness, headache, neck pain, blurred vision or (pre-) syncope.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT02669056
Sponsor: Assistance Publique Hopitaux De Marseille (Academic / non-profit / other)
Intervention(s): 5-Ht Measurement, Cerebral Mri, Video Recording, Eeg, Growth Curves
Start: Dec 2015  |  Primary completion: Jan 2019  |  Enrollment: 34 (actual)
Record last updated: May 2023

Although significant advances in neonatal care have increased survival rates of preterm infants born before 28 weeks gestation, a concomitant decrease in neuro developmental disorders has not been achieved. Cerebral injuries, well documented during the previous years, in preterm babies are particularly deleterious since they occur in a developing brain.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT03903666
Sponsor: Institut Jerome Lejeune (Academic / non-profit / other)
Intervention(s): Nocturnal Gaz Exchanges Measurement
Start: Oct 2019  |  Primary completion: Mar 2022  |  Enrollment: 48 (actual)
Record last updated: Mar 2023

Recently, retrospective studies have shown that Down Syndrome children have a higher CO2 (carbone dioxide) sleep pressure than the general pediatric population. This increase does not seem to be always related to sleep apnea. The Investigators wish to confirm these results prospectively.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT03032328
Sponsor: Wake Forest University Health Sciences (Academic / non-profit / other)
Intervention(s): Vitamin D Supplement
Start: Jun 2016  |  Primary completion: Dec 2022  |  Enrollment: 31 (actual)
Record last updated: Jan 2023

In previous work the investigator identified a group of children between the ages of 10-18 years whose diagnostic workup for chronic nausea unexplained by conventional diagnostic tests has unexpectedly revealed underlying cardiovascular instability manifesting as orthostatic intolerance, primary defined as postural orthostatic tachycardia syndrome (POTS) (88%).

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05404672
Sponsor: Riphah International University (Academic / non-profit / other)
Intervention(s): Aerobic Training, Conventional Treatment
Start: Jun 2022  |  Primary completion: Dec 2022  |  Enrollment: 28 (actual)
Record last updated: Jan 2023

Postural orthostatic tachycardia syndrome (POTS) is a chronic, multifactorial syndrome with complex symptoms of orthostatic intolerance. Of the major complaints are breathlessness and exercise intolerance. The aim is to explore the potential impact of a physiotherapy intervention involving education and breathing control on dysfunctional breathing and improving exercise intolerance in POTS.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05194059
Sponsor: Scientific Institute San Raffaele (Academic / non-profit / other)
Intervention(s): Home-Based Physical Activity
Start: Dec 2021  |  Primary completion: Oct 2022  |  Enrollment: 24 (actual)
Record last updated: Jan 2023

Physical activity helps to improve health and prevent chronic diseases. However, the fatigue usually hampers the training and execution of physical exercises, especially in people with chronic fatigue syndromes (CFCs), such as persons living with HIV (PLWH).

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT04978740
Sponsor: Poitiers University Hospital (Academic / non-profit / other)
Intervention(s): Ophthalmological Examination
Start: Jul 2021  |  Primary completion: Sep 2021  |  Enrollment: 21 (actual)
Record last updated: Dec 2022

Mastocytosis is a rare condition characterized by an accumulation of mast cell cells in one or more organs such as the liver, bone marrow, spleen and intestines. Its prevalence in the general population is 1 in 10,000. This pathology is due to the proliferation of a mast cell clone and the excessive release of inflammatory mediators which lead to abnormal tissue infiltration.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT04996212
Sponsor: University of Valencia (Academic / non-profit / other)
Intervention(s): Walking App Group, Functional App Group
Start: Jan 2021  |  Primary completion: Oct 2022  |  Enrollment: 70 (actual)
Record last updated: Oct 2022

The syndrome characterized by the persistence of symptoms typical of COVID-19, beyond 4 weeks after discharge, is called long COVID. Long COVID affects a high percentage of patients who have suffered from COVID-19, regardless of its severity. The various symptoms present in that patients affect the functionality and physical, mental and psychological capacities of patients.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT04845737
Sponsor: Abant Izzet Baysal University (Academic / non-profit / other)
Intervention(s): Sympathetic Skin Response Measurement
Start: Jun 2021  |  Primary completion: Jul 2022  |  Enrollment: 120 (actual)
Record last updated: Oct 2022

Fibromyalgia Syndrome (FMS); It is a chronic condition characterized by widespread body pain, sleep disturbance, fatigue, impaired cognitive functions, and anxiety (1).

View on ClinicalTrials.gov ↗
CompletedEarly Phase 1 NCT03261570
Sponsor: New York Medical College (Academic / non-profit / other)
Intervention(s): Pyridostigmine, Digoxin
Start: Jul 2017  |  Primary completion: Jun 2022  |  Enrollment: 51 (actual)
Record last updated: Sep 2022

Postural tachycardia syndrome (POTS), is the chronic form of orthostatic intolerance associated with excessive upright tachycardia, and occurs predominantly in young females (\>85%). Among its most troubling symptoms are lightheadedness, fatigue, and decreased memory often called "brain fog" by patients.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT02460445
Sponsor: Manuel Luque Ramírez (Academic / non-profit / other)
Intervention(s): Phlebotomy, Cyproterone Acetate
Start: Jan 2015  |  Primary completion: Jun 2020  |  Enrollment: 37 (actual)
Record last updated: Jul 2022

AIMS To study the effects of the decrease in iron tissue depots after scheduled bloodletting on insulin sensitivity, carbohydrate metabolism, classic and non-classic cardiovascular risk factors in patients with functional hyperandrogenism (polycystic ovary syndrome \& idiopathic hyperandrogenism) on standard treatment with combined oral contraceptives (COC) according to usual clinical practice.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT03253120
Sponsor: Insel Gruppe AG, University Hospital Bern (Academic / non-profit / other)
Intervention(s): Water
Start: Sep 2017  |  Primary completion: Apr 2022  |  Enrollment: 30 (actual)
Record last updated: Jul 2022

The Postural Tachycardia-Syndrome (POTS) is a form of autonomic dysregulation, typically accompanied by symptoms of orthostatic intolerance (OI). OI is defined by the inability to tolerate the upright position and is improved by lying down. POTS is considered a syndrome that may include a number of several disorders.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT01764711
Sponsor: Vanderbilt University (Academic / non-profit / other)
Intervention(s): Cosyntropin Administration
Start: Jan 2013  |  Primary completion: Dec 2020  |  Enrollment: 13 (actual)
Record last updated: Mar 2022

This study is to determine different chemical levels in the blood during a low salt diet. This study will compare normal volunteers to those with Postural Tachycardia Syndrome (POTS).

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT04603157
Sponsor: Mayo Clinic (Academic / non-profit / other)
Intervention(s): Hybrid Exercise Training
Start: Jan 2020  |  Primary completion: Feb 2022  |  Enrollment: 60 (actual)
Record last updated: Mar 2022

The purpose of this research is to evaluate if a hybrid semi-supervised remote exercise training program can reduce symptoms and improve quality of life and physical fitness in individuals with postural orthostatic tachycardia syndrome (POTS) and determine if this program is more effective than current standard of care.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT01547117
Sponsor: Vanderbilt University (Academic / non-profit / other)
Intervention(s): Blood Volume, Total Blood Volume, Exercise Capacity Test - Bicycle, Posture Study
Start: Mar 2012  |  Primary completion: Dec 2020  |  Enrollment: 38 (actual)
Record last updated: Feb 2022

Patients with POTS may not adequately expand their plasma volume in response to a high-sodium (Na+) diet.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT02553265
Sponsor: NYU Langone Health (Academic / non-profit / other)
Intervention(s): Carbidopa Low-Dose, Carbidopa High-Dose
Start: Sep 2015  |  Primary completion: May 2019  |  Enrollment: 22 (actual)
Record last updated: Feb 2022

The overall study objectives are to determine whether carbidopa (Lodosyn®) is safe and well tolerated and to assess whether it can inhibit catecholamine-induced paroxysmal hypertension and normalize or reduce the exaggerated blood pressure variability in patients with familial dysautonomia (FD, also called hereditary sensory and autonomic neuropathy type III or Riley-Day syndrome). Funding Source- FDA OOPD.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT01563107
Sponsor: Vanderbilt University Medical Center (Academic / non-profit / other)
Intervention(s): Plasma Volume, Exercise Capacity Test - Bicycle, Posture Study
Start: Mar 2012  |  Primary completion: Dec 2020  |  Enrollment: 38 (actual)
Record last updated: Jan 2022

Patients with Postural Tachycardia Syndrome (POTS) may not adequately expand their plasma volume in response to a high sodium diet. Mechanisms involved in the regulation of plasma volume, such as the renin-angiotensin-aldosterone system and renal dopamine (DA), may be impaired in POTS and may respond inappropriately to changes in dietary sodium.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT00685919
Sponsor: Vanderbilt University (Academic / non-profit / other)
Intervention(s): Carbidopa
Start: May 2008  |  Primary completion: Jul 2020  |  Enrollment: 32 (actual)
Record last updated: Jan 2022

The purpose of the proposed research is to determine how changes in kidney dopamine (DA) activity influence urinary sodium excretion. We will decrease DA activity in the kidney by inhibiting DA synthesis via carbidopa administration. We want to compare findings in normal volunteers and in patients with postural tachycardia syndrome (POTS).

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT01550315
Sponsor: Vanderbilt University Medical Center (Academic / non-profit / other)
Intervention(s): Pulsitile Arterial Tonometry (Pat) Protocol, Calf Blood Flow In Reactive Hyperemia, Evaluation Of Forearm-Mediated Dilation
Start: Apr 2012  |  Primary completion: Dec 2020  |  Enrollment: 27 (actual)
Record last updated: Jan 2022

The investigators will test the hypothesis that markers of vascular endothelial dysfunction will be exaggerated acutely with an extreme high sodium diet compared to an extreme low-sodium diet. The investigators will compare patients with postural orthostatic tachycardia (POTS) to healthy control subjects.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT03484273
Sponsor: University of Calgary (Academic / non-profit / other)
Intervention(s): Lifewrap Compression Garment
Start: Jul 2018  |  Primary completion: Apr 2020  |  Enrollment: 32 (actual)
Record last updated: Oct 2021

When an individual with Postural Tachycardia Syndrome (POTS) stands up, their heart rate increases significantly (\>30BPM) and they may experience symptoms such as lightheadedness, dizziness, shortness of breath, nausea and mental confusion. One commonly prescribed treatment for POTS is compression garments.

View on ClinicalTrials.gov ↗
CompletedPhase 3 NCT03182725
Sponsor: University of California, San Diego (Academic / non-profit / other)
Intervention(s): Ivabradine
Start: Feb 2018  |  Primary completion: May 2020  |  Enrollment: 37 (actual)
Record last updated: Jun 2021

Postural orthostatic tachycardia syndrome (POTS) occurs in approximately 500,000 Americans, but predominates in women with a 5:1 ratio. Patients with POTS experience debilitating tachycardia upon postural changes such as standing that impairs their quality of life.

View on ClinicalTrials.gov ↗
CompletedEarly Phase 1 NCT01210430
Sponsor: New York Medical College (Academic / non-profit / other)
Intervention(s): Losartan, Ascorbic Acid, Normal Saline
Start: Jul 2010  |  Primary completion: Jun 2015  |  Enrollment: 74 (actual)
Record last updated: Jun 2021

The investigators study will determine how often blood flow regulation abnormalities and abnormalities of sympathetic regulation produced by nitric oxide, angiotensin-II, and oxidative stress occur in POTS and the mechanism(s) of POTS in individual patients. Specific causes for POTS may vary from patient to patient. Patients will be compared to healthy control subjects.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT03990142
Sponsor: Fondation Hôpital Saint-Joseph (Academic / non-profit / other)
Intervention(s): Cutaneous Conductance To Chlorine By Sudoscan
Start: Jun 2019  |  Primary completion: May 2020  |  Enrollment: 176 (actual)
Record last updated: Jun 2021

Intradialytic hypotension is a common complication of hemodialysis sessions in patients with chronic renal failure, with an estimated prevalence of 10 to 30%. This hypotensopn is classically defined by a decrease in systolic blood pressure greater than 30 mmHg associated with clinical signs (cramps, abdominal pain, unconsciousness, convulsions).

View on ClinicalTrials.gov ↗
CompletedPhase 1 NCT04121338
Sponsor: Johns Hopkins University (Academic / non-profit / other)
Intervention(s): Celiac Ganglion Block, Liposomal Bupivacaine
Start: Dec 2019  |  Primary completion: May 2021  |  Enrollment: 15 (actual)
Record last updated: May 2021

Dysautonomia is malfunction of the autonomic nervous system. It usually results from overactivity of the sympathetic portion and over-secretion of acetylcholine. Symptoms depend on the organ involved by this sympathetic overstimulation.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT04875949
Sponsor: Istituto Clinico Humanitas (Academic / non-profit / other)
Intervention(s): Immunoabsorption/Plasmapheresis Procedure
Start: Apr 2016  |  Primary completion: Jan 2019  |  Enrollment: 75 (actual)
Record last updated: May 2021

Anti alfa-3 and alfa-7 ganglionic cholinergic receptors (anti-AChRs) antibodies (Abs) plasma removal by plasmapheresis (1,2) acutely improved dysautonomia symptoms in case reports with Pure Autonomic Failure (PAF) (3).

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT03602482
Sponsor: Milton S. Hershey Medical Center (Academic / non-profit / other)
Intervention(s): Standing, Supine
Start: Jun 2018  |  Primary completion: Dec 2019  |  Enrollment: 139 (actual)
Record last updated: Apr 2021

The purpose of this study is to evaluate cognition in patients with postural tachycardia syndrome (POTS) while lying down and standing and to assess the prevalence of hypermobile Ehlers-Danlos Syndrome in POTS.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT01607073
Sponsor: Gillette Children's Specialty Healthcare (Academic / non-profit / other)
Intervention(s): Verapamil
Start: Apr 2012  |  Primary completion: Jan 2015  |  Enrollment: 2 (actual)
Record last updated: Apr 2021

This study will assess how well the drug verapamil can improve control of seizures and dysautonomia symptoms in children and young adults diagnosed with Dravet syndrome. The safety of verapamil when given with all concomitant medications will also be assessed.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT04821882
Sponsor: National Defense Medical Center, Taiwan (Academic / non-profit / other)
Intervention(s): Dextrose
Start: May 2019  |  Primary completion: Sep 2020  |  Enrollment: 29 (actual)
Record last updated: Apr 2021

The pathogenesis of bladder pain syndrome/interstitial cystitis (BPS/IC) is currently unclear. Scholars have put forward different hypotheses, including the function of the extracellular matrix surface of the glycosaminoglycan (GAG) layer, downregulation of tight junction protein, increased urothelial permeability, mast cell activation, neurogenic inflammation, and psychosomatic factors.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT02276716
Sponsor: NYU Langone Health (Academic / non-profit / other)
Intervention(s): Phosphatidylserine
Start: Nov 2011  |  Primary completion: Aug 2019  |  Enrollment: 26 (actual)
Record last updated: Feb 2021

Familial dysautonomia (FD) is a devastating hereditary disease in which the development of selective neuronal populations is impaired because of a deficiency of the protein IKAP (Slaugenhaupt, 2002). There is no known cure. Treatments are supportive, often ineffective and around half of all patients die before reaching age 40 (Axelrod et al., 2002).

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT03784339
Sponsor: Manchester Metropolitan University (Academic / non-profit / other)
Intervention(s): Physiotherapy
Start: Mar 2019  |  Primary completion: Aug 2019  |  Enrollment: 24 (actual)
Record last updated: Feb 2020

Feasibility study: Does a designated education session change levels of catastrophizing, kinesiophobia and pain beliefs in patients with patellofemoral pain? Design: Single site feasibility Study Aim: Aims are to identify if a formal education session (intervention) improves patient outcomes and to assess if it is possible to test the intervention for efficacy in a larger study.

View on ClinicalTrials.gov ↗
CompletedPhase 1 NCT02955420
Sponsor: Berlin Cures GmbH (Industry)
Intervention(s): BC 007 (Aptamer), N-Acetylcysteine (NAC)
Start: Aug 2016  |  Primary completion: Apr 2018  |  Enrollment: 74 (estimated)
Record last updated: Jul 2018

Berlin Cures develops BC 007 to treat patients suffering from diseases (chronic heart failure, pulmonary hypertension, chronic fatigue syndrome etc.) which are associated with functional autoantibodies (AAB) directed against G-protein coupled receptors (GPCR). The first part of the study (part A) is designed to evaluate the safety and tolerability of ascending doses of BC 007.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT01713725
Sponsor: Clinica Universidad de Navarra, Universidad de Navarra (Academic / non-profit / other)
Intervention(s): Omalizumab
Start: Mar 2012  |  Primary completion: Feb 2016  |  Enrollment: 20 (actual)
Record last updated: Oct 2017

Chronic urticaria can be defined as the occurrence of widespread daily or almost daily wheals for at least 6 weeks, which may be accompanied by angioedema. While the wheals are transient, the resolution of angioedema is slower than wheals and could take up to 72 hours. The natural course of chronic urticaria is self-limited, with spontaneous remissions and occasional relapses.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT02454244
Sponsor: Hospital Miguel Servet (Academic / non-profit / other)
Intervention(s): Art With Mindfulness, Mindfulness Compassion, Relaxation
Start: Jun 2015  |  Primary completion: Dec 2015  |  Enrollment: 60 (actual)
Record last updated: Aug 2017

Amygdala Retraining Treatment (ART) is a new and promising therapy for patients with Chronic Fatigue Syndrome (CFS) and Fibromyalgia (FM), however, randomized controlled trials (RCT) are scarce. The investigators have added mindfulness to this therapy, based on preliminary reports of its efficacy on patients, obtaining Amygdala Retraining Treatment with Mindfulness (ART+MF).

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT02816060
Sponsor: Universidad Rey Juan Carlos (Academic / non-profit / other)
Intervention(s): Manual Therapy
Start: May 2016  |  Primary completion: Nov 2016  |  Enrollment: 54 (actual)
Record last updated: Mar 2017

There is evidence linking conditioned pain modulation (CPM) deficiency with musculoskeletal pain syndromes such as fibromyalgia, migraine, tension-type headaches and irritable bowel syndrome, as well as with temporomandibular disorders, idiopathic facial pain and chronic fatigue syndrome. Evidence shows that in pre-surgical situations of chronic pain there is no activation of CPM.

View on ClinicalTrials.gov ↗
CompletedPhase 3 NCT00007748
Sponsor: US Department of Veterans Affairs (US federal agency)
Intervention(s): Aerobic Exercise, Cognitive Behavioral Therapy
Start: Mar 1999  |  Primary completion: Unknown  |  Enrollment: 1064
Record last updated: Jun 2015

This trial is a study of Gulf War era veterans who have unexplained chronic medical symptoms such as pain, fatigue, and/or cognitive difficulties. The treatments to be studied, cognitive behavior therapy (CBT) and aerobic exercise, have been shown to be effective in alleviating symptoms in individuals with other similar types of illnesses, such as chronic fatigue syndrome and fibromyalgia.

View on ClinicalTrials.gov ↗
CompletedPhase 4 NCT01316718
Sponsor: University of Nottingham (Academic / non-profit / other)
Intervention(s): Mesalazine
Start: Mar 2011  |  Primary completion: Sep 2013  |  Enrollment: 108 (actual)
Record last updated: Jan 2014

The purpose of the trial is to define the clinical benefit and possible mediators of the benefit of mesalazine in Irritable Bowel Syndrome (IBS) with diarrhoea. The investigators will therefore evaluate symptoms (primarily bowel frequency) and markers reflecting mast cell activation and small bowel tone.

View on ClinicalTrials.gov ↗

Terminated (5)

TerminatedPhase 2 NCT05652907
Sponsor: Quantum Biopharma (Industry)
Intervention(s): Fsd201
Start: Jan 2023  |  Primary completion: May 2023  |  Enrollment: 2 (actual)
Record last updated: Apr 2026

This study will determine if FSD201 reduces the average daily 24-hour recall pain intensity after 28 and 56 days of treatment in adults with chronic widespread musculoskeletal nociplastic pain.

View on ClinicalTrials.gov ↗
TerminatedPhase 2 NCT02558972
Sponsor: New York Medical College (Academic / non-profit / other)
Intervention(s): Northera
Start: Sep 2015  |  Primary completion: Dec 2022  |  Enrollment: 30 (estimated)
Record last updated: May 2025

Vasovagal syncope (VVS, simple faint) is the most common cause of transient loss of consciousness and represents the acute episodic form of orthostatic intolerance (OI). Postural tachycardia syndrome (POTS) is the common chronic form of OI. Both are defined by debilitating symptoms and signs while upright relieved by recumbency.

View on ClinicalTrials.gov ↗
TerminatedPhase 4 NCT04313972
Sponsor: Endeavor Health (Academic / non-profit / other)
Intervention(s): Low-Dose Naltrexone (LDN)
Start: Sep 2021  |  Primary completion: Jan 2023  |  Enrollment: 3 (actual)
Record last updated: Mar 2025

Interstitial cystitis/painful bladder syndrome (IC/PBS) is a debilitating condition with symptoms of urinary urgency, frequency, nocturia (waking up at night to void), and pain, without evidence of urinary tract infection or other identifiable causes. IC/PBS often coexists with other chronic pain syndromes, such as irritable bowel syndrome, chronic fatigue syndrome, and fibromyalgia.

View on ClinicalTrials.gov ↗
TerminatedPhase not applicable NCT04652843
Sponsor: Nantes University Hospital (Academic / non-profit / other)
Intervention(s): Rectosignoidoscopy, Coloscopy
Start: Dec 2020  |  Primary completion: Jan 2024  |  Enrollment: 77 (actual)
Record last updated: Feb 2024

Converging evidence from the literature suggests that digestive inflammation may play a role in the development of Parkinson's disease (PD). The investigators showed in the laboratory in a pilot study that PD patients have digestive inflammation and that the level of inflammation was inversely related to the length of the disease course.

View on ClinicalTrials.gov ↗
TerminatedPhase 4 NCT03191201
Sponsor: Prof Gérard WAEBER (Academic / non-profit / other)
Intervention(s): Ferric Carboxymaltose
Start: Jun 2017  |  Primary completion: Mar 2020  |  Enrollment: 32 (actual)
Record last updated: Mar 2020

In this study the investigators aim at addressing potential relationships between iron stores and glucose homeostasis. Iron (i.e. Ferric Carboxymaltose) will be perfused to pre-menopausal, iron-deficient non-anaemic women suffering from a chronic fatigue syndrome and parameters related to glucose homeostasis, parameters related to metabolic syndrome and inflammation will be measured before and after the intervention.

View on ClinicalTrials.gov ↗

Withdrawn (4)

WithdrawnPhase 3 NCT03365414
Sponsor: University of Alberta (Academic / non-profit / other)
Intervention(s): Albumin (Human) 5%, Usp
Start: Jan 2022  |  Primary completion: Oct 2023
Record last updated: Sep 2024

POTS is a relatively common condition that affects millions of patients around the globe. It has an estimated prevalence of 170/100,000 with approximately 80% of patients being women of childbearing age. POTS is characterized by an excessive heart rate increase on assuming an upright posture, either standing or even sitting and leading to disabling palpitations, light-headedness, and even in syncope in severe cases.

View on ClinicalTrials.gov ↗
WithdrawnPhase 2 NCT04855266
Sponsor: Mayo Clinic (Academic / non-profit / other)
Intervention(s): Sucrose, Tilt Table Test
Start: Apr 2021  |  Primary completion: May 2023
Record last updated: Jun 2023

This study aims to investigate whether the treatment of non-anemic iron deficiency with intravenous iron sucrose will result in decreased symptom reporting and improved cardiovascular indices in patients with Postural Orthostatic Tachycardia syndrome (POTS).

View on ClinicalTrials.gov ↗
WithdrawnPhase not applicable NCT02316132
Sponsor: University Hospital Schleswig-Holstein (Academic / non-profit / other)
Intervention(s): Stress
Start: Dec 2014  |  Primary completion: Jun 2016
Record last updated: Jul 2022

After standard endomicroscopy with fluorescein to investigate for dysplasia in Barrett's esophagus the endoscope will be forwarded into the 2nd part of the duodenum. Fluorescein is needed for CLE but is not part of the investigation.

View on ClinicalTrials.gov ↗
WithdrawnPhase not applicable NCT04702217
Sponsor: Lund University (Academic / non-profit / other)
Intervention(s): Training Program
Start: Oct 2021  |  Primary completion: Jul 2022
Record last updated: Dec 2021

Postural orthostatic tachycardia syndrome (POTS) is a disorder of unknown origin characterized by orthostatic intolerance and increased heart rate (HR) of ≥ 30 beats/minute during orthostasis in the absence of orthostatic hypotension.

View on ClinicalTrials.gov ↗

Unknown status (16)

Unknown statusPhase not applicable NCT06865261
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Academic / non-profit / other)
Intervention(s): Bioarginina C
Start: May 2024  |  Primary completion: Oct 2025  |  Enrollment: 100 (estimated)
Record last updated: Mar 2025

In older age, reduced mobility is associated with an increased risk of reduced quality of life, disability, institutionalisation, and death, as well as increased healthcare expenditures. Sarcopenia is a condition characterised by a reduction in muscle mass and strength and/or function.

View on ClinicalTrials.gov ↗
Unknown statusPhase 3 NCT06055270
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (Academic / non-profit / other)
Intervention(s): Stellate Ganglion Block
Start: Feb 2024  |  Primary completion: Dec 2025  |  Enrollment: 44 (estimated)
Record last updated: Oct 2024

Chronic olfactory dysfunction, both hyposmia and parosmia, from the COVID-19 pandemic is a growing public health crisis, affecting up to 1.2 million people in the United States. Olfactory dysfunction significantly impacts one's quality of life by decreasing the enjoyment of foods, creating environmental safety concerns, and affecting one's ability to perform specific jobs.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05409651
Sponsor: University of California, San Diego (Academic / non-profit / other)
Intervention(s): Time Restricted Eating
Start: Jul 2022  |  Primary completion: May 2024  |  Enrollment: 25 (actual)
Record last updated: Aug 2024

The mechanisms underlying POTS are not well understood. Though heterogeneous in nature, patients often present with symptoms that include fatigue, orthostatic lightheadedness and tachycardia, "brain fog", shortness of breath, and sleep disruption. The central mediator that links observations in disease entities similar to POTS is energy use and balance driven by mitochondrial health.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT06554834
Sponsor: SomaticMed (Academic / non-profit / other)
Intervention(s): Cv4 + Rr, Cv4, Eeg/Hrv/Rsa (Electroencephalography, Heart Rate Variability, Respiratory Sinus Arrhythmia) Monitoring Using Infiniti System
Start: Jun 2024  |  Primary completion: Oct 2024  |  Enrollment: 109 (estimated)
Record last updated: Aug 2024

Cranial osteopathic manipulation technique for brain and cranial nerve function, known as the fourth ventricle compression (CV4), has been recognized. Rib raising (RR), aimed at reducing rib restriction and conditions associated with sympathetic hypertonia, is also employed.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT06097572
Sponsor: Imperial College London (Academic / non-profit / other)
Intervention(s): Intranasal Food Challenge, Mast Cell Activation Test
Start: Oct 2023  |  Primary completion: Jul 2025  |  Enrollment: 166 (estimated)
Record last updated: Mar 2024

The investigators will conduct low-dose intranasal allergen challenges on children and young people with an indeterminate diagnosis of food allergy to cow's milk or peanut. Blood samples will also be taken, for conventional blood allergy diagnostics (allergy-specific Immunoglobulin E) and mast cell activation test (MAT).

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05309772
Sponsor: King's College London (Academic / non-profit / other)
Intervention(s): Basophil Activation Test, Oral Food Challenge
Start: Jan 2023  |  Primary completion: Jul 2025  |  Enrollment: 398 (estimated)
Record last updated: Sep 2023

The BAT Impact study is a prospective multicentre study in the UK using a biomarker-led study design to compare the incidence of adverse events (defined as allergic reactions during oral food challenges) in a randomized-controlled trial.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05951803
Sponsor: Hospital General de Mexico (Other government)
Intervention(s): Brief Behavioral Intervention In Insomnia
Start: Jun 2023  |  Primary completion: Dec 2023  |  Enrollment: 36 (estimated)
Record last updated: Jul 2023

The COVID-19 pandemic represented a global public health problem that brought considerable consequences to the physical and mental health of the entire population.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05923840
Sponsor: New York Medical College (Academic / non-profit / other)
Intervention(s): Chemoreflex Testing, Baroreflex Testing, Orthostatic Stress Testing
Start: Sep 2022  |  Primary completion: Aug 2023  |  Enrollment: 30 (estimated)
Record last updated: Jun 2023

Postural tachycardia syndrome (POTS) is the most common chronic cause of postural lightheadedness, and upright confusion afflicting many Americans, mostly young women. Many POTS patients hyperventilate by increasing their depth of breathing that produces tachycardia, alters blood flow and blood pooling in the body and importantly reduces brain blood flow causing "brain fog".

View on ClinicalTrials.gov ↗
Unknown statusPhase 2 NCT05449444
Sponsor: AB Science (Industry)
Intervention(s): Masitinib 4.5 Mg/Kg/Day, Best Supportive Care, Masitinib 6.0 Mg/Kg/Day
Start: Jul 2022  |  Primary completion: Dec 2024  |  Enrollment: 72 (estimated)
Record last updated: Feb 2023

To evaluate the efficacy and safety of two dosing schemes of oral masitinib versus matching placebo in the treatment of patients suffering from severe MCAS with handicap unresponsive to optimal symptomatic treatment.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT04632134
Sponsor: Istituto Clinico Humanitas (Academic / non-profit / other)
Intervention(s): Transcutaneous Vagal Nerve Stimulation, Home Daily Transcutaneous Vagal Nerve Stimulation
Start: Nov 2019  |  Primary completion: Jun 2022  |  Enrollment: 23 (estimated)
Record last updated: Jun 2022

Postural Orthostatic Tachycardia Syndrome (POTS) is characterized by symptoms of chronic orthostatic intolerance such as fatigue, lightheadedness, dizziness, palpitations and by pronounced tachycardia upon standing.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT03724370
Sponsor: VA Pittsburgh Healthcare System (US federal agency)
Intervention(s): Telehealth Monitoring System, Vha-Srm
Start: Dec 2018  |  Primary completion: Dec 2023  |  Enrollment: 180 (estimated)
Record last updated: May 2022

Overview. The investigators will randomize 120 Veterans in this 3-site trial over 16 months. Eligible Veterans will include those to be discharged for a hospitalization for suicidal ideation.

View on ClinicalTrials.gov ↗
Unknown statusPhase 2 NCT05084872
Sponsor: University Hospital, Toulouse (Academic / non-profit / other)
Intervention(s): Hydroxychloroquine
Start: Oct 2021  |  Primary completion: Jan 2024  |  Enrollment: 30 (estimated)
Record last updated: Oct 2021

The treatment of systemic mastocytosis has two main axes: * Control of mast cell activation symptoms and * The control of proliferation (accumulation) of mast cells. There is no standard treatment and no treatment has a marketing authorization for the treatment of monoclonal indolent mastocytosis.

View on ClinicalTrials.gov ↗
Unknown statusPhase 4 NCT03789422
Sponsor: University Hospital, Grenoble (Academic / non-profit / other)
Intervention(s): Association Of Levocetirizine And Tranexamic Acid, Levocetirizine Only
Start: Dec 2019  |  Primary completion: Sep 2022  |  Enrollment: 80 (estimated)
Record last updated: Apr 2021

Spontaneous chronic urticaria (UCS) is a disease that affects 1% of the general population with a potentially severe impact on quality of life. Most patients respond favorably to long-term antihistamine treatment, but sometimes it is necessary to give a high dose (4 times the formal dose, Berlin consensus 2016). These high doses are often accompanied by side effects requiring cessation of treatment.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT02246088
Sponsor: University of Valencia (Academic / non-profit / other)
Intervention(s): Mt + Ne, Mt + E
Start: Dec 2013  |  Primary completion: Dec 2015  |  Enrollment: 53 (estimated)
Record last updated: Sep 2014

Osteoarthritis (OA) is a frequent chronic musculoskeletal pathology that usually causes great disability and significant healthcare costs. Substantial scientific evidence indicates a role for central sensitization in OA pain.

View on ClinicalTrials.gov ↗
Unknown statusPhase 4 NCT01417923
Sponsor: Meir Medical Center (Academic / non-profit / other)
Intervention(s): Vitamin D
Start: Sep 2011  |  Primary completion: Dec 2012  |  Enrollment: 80 (estimated)
Record last updated: Nov 2012

Vitamin D3 is produced in the skin following exposure to UVB light from the sun or artificial sources, and occurs naturally in a small range of foods.More recently, several reports underlined the impact of vitamin D on the prevalence and consequences of inadequate vitamin D intake and the research supporting its benefits for alleviating chronic musculoskeletal pain and fatigue syndromes in outpatients.

View on ClinicalTrials.gov ↗

Frequently asked questions

Does the Open Source Medicine Foundation run these trials?

No. OSMF does not sponsor, run or recruit for any trial on this page. We compile public registry entries from ClinicalTrials.gov so patients and clinicians can find them in one place. For questions about a specific study, contact the sponsor or study team listed on its ClinicalTrials.gov record.

What do the trial phases mean?

Early Phase 1 / Phase 1 studies test safety and dosing in a small group. Phase 2 studies look for a signal of benefit in a larger group and keep checking safety. Phase 3 studies are large confirmatory trials designed to show whether a treatment works well enough for approval. Phase 4 studies follow approved treatments after they reach the market. "Phase not applicable" is used by the registry for behavioural, device, rehabilitation and other non-drug interventions.

Why is a trial I know about missing?

Our search targets interventional studies whose registered conditions map to Long COVID / PASC, ME/CFS or overlapping post-viral syndromes. Observational studies, trials registered only on non-US registries (EU CTR, ISRCTN, ANZCTR, etc.), and trials whose condition terms did not match our mapping are not included. The full ClinicalTrials.gov search is always more complete than any curated index.

What does "terminated" or "withdrawn" mean?

Terminated means the study started but stopped early, for reasons that can include lack of funding, slow recruitment, safety signals or clear futility; the record often states why. Withdrawn means the study was cancelled before enrolling anyone. Suspended means enrolment is paused and may resume.

Get new recruiting trials in your inbox.

We summarise newly registered post-viral trials and notable results on the OSMF Substack.

Subscribe on Substack
Cite this page
Open Source Medicine Foundation. All post-viral overlap clinical trials on ClinicalTrials.gov (155 trials, updated October 2026). Research Tracker, 07 October 2026. https://research.opensourcemed.info/trials/all-post-viral-overlap.html
Underlying dataset (JSON, CC BY 4.0): https://research.opensourcemed.info/data/clinical_trials/clinical_trials_current.json. Source records: ClinicalTrials.gov.

Related: recruiting post-viral overlap trials · post-viral overlap research hub · interactive trial finder.